Last reviewed · How we verify

M-VTD-PACE — Competitive Intelligence Brief

M-VTD-PACE (M-VTD-PACE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy and immunotherapy regimen. Area: Oncology.

phase 3 Combination chemotherapy and immunotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

M-VTD-PACE (M-VTD-PACE) — University of Arkansas. M-VTD-PACE is a combination chemotherapy and immunotherapy regimen that uses multiple agents to target and kill multiple myeloma cells through different mechanisms.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
M-VTD-PACE TARGET M-VTD-PACE University of Arkansas phase 3 Combination chemotherapy and immunotherapy regimen
Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib University of Ulm phase 3 Combination chemotherapy and immunotherapy regimen CD20 (rituximab), proteasome (bortezomib), DNA alkylation (cyclophosphamide), glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy and immunotherapy regimen class)

  1. University of Arkansas · 1 drug in this class
  2. University of Ulm · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). M-VTD-PACE — Competitive Intelligence Brief. https://druglandscape.com/ci/m-vtd-pace. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: